Every part of the medical innovation ecosystem must work together if the federal government is serious about the successful implementation of its Alzheimer's plan, PhRMA President and CEO John J. Castellani writes. Strong partnerships and collective thinking among biopharmaceutical research companies, patient advocacy groups, federal research institutions and universities are needed to find efficient remedies to mitigate the financial and emotional burdens of Alzheimer's and other conditions, Castellani writes. Short-sighted policies that weaken progress and innovation should not endanger the country's strong research enterprise, he adds.

Full Story:
Hill, The

Related Summaries